Altimmune to Report First Quarter 2022 Financial Results and Provide Business Update on May 12

George T. Taft
Altimmune, Inc

Altimmune, Inc

GAITHERSBURG, Md., May 05, 2022 (World NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a scientific-phase biopharmaceutical firm, now declared that it will report its initial quarter 2022 economical effects on Thursday, May well 12, 2022 and will supply a company update.

Altimmune administration will host a convention get in touch with at 8:30 am E.T. on Might 12 to focus on financial benefits and provide a business enterprise update.

Meeting Call Data:

About Altimmune

Altimmune is a medical-stage biopharmaceutical corporation centered on the growth of novel peptide-based therapeutics for the remedy of weight problems and liver illnesses. The company’s lead solution candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is currently being created for the treatment of weight problems and NASH. In addition, Altimmune is producing HepTcell™, an immunotherapeutic created to reach a useful overcome for chronic hepatitis B. For additional information, you should go to www.altimmune.com.

Stick to @Altimmune, Inc. on LinkedIn
Abide by @AltimmuneInc on Twitter

Investor and Media Contact:

Richard Eisenstadt
Main Economic Officer
Cellphone: 240-654-1450
reisenstadt@altimmune.com

Next Post

Small Business Week Spotlight: 5 Exceptional Franchisees

A lesser identified actuality about franchises is that franchisees perform as compact small business owners, and typically thrive independently by bringing their very own passions and thoughts to the business. In honor of National Small Company Week, we’re highlighting outstanding franchisees who have gone over and over and above for their […]